General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Specialty

Novartis has a diverse portfolio of medications to treat disorders that affect the body’s immune response and occur when the immune system is overactive and/or begins to fight against itself. In Integrated Hospital Care, our focus is on the following disease areas:

Transplantation

We have a broad portfolio of immunosuppressants. These include Neoral (cyclosporine), Simulect (basiliximab), myfortic (micophenolic acid) and Certican/Zortress (everolimus).

Nephrology / Hepatitis

Our portfolio includes Tyzeka/Sebivo (telbivudine).

Autoinflammatory and autoimmune diseases

An important product in this disease area is Ilaris (canakinumab).